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Background: Overexpression of the tumor suppressor gene p53 and the marker for cellular proliferation Ki67 in
open lung biopsies are indicated as predictor factors of survival of patients with lung cancer. However, the
prognostic value of p53 and Ki67 in fiberoptic bronchial biopsies (FBB) has not been fully investigated. We
evaluated p53 and Ki67 immunostaining in FBB from 19 with Non Small-Cell Lung Cancer (NSCLC: 12
adenocarcinomas, 5 squamous cell carcinomas and 2 NSCLC-NOS).
Methods: FBB specimens were fixed in formalin, embedded in paraffin, and immunostained using anti-p53 and
anti-Ki67 antibodies. Slides were reviewed by two independent observers and classified as positive (+ve) when the
number of cells with stained nuclei exceeded 15% for p53 or when >25% positive cells were observed throughout
each section for Ki67.
Results: Positive (+ve) immunostaining was found in 9 patients for p53 (47.37%) and 8 patients for Ki67 (42.10%).
We examined overall survival curves of the patients with Mantel's logrank test, both p53 -ve and Ki67 -ve patients
had significantly higher survival rates than p53 + ve (p < 0.005) and Ki67 + ve (p < 0,0001), respectively.
Conclusion: This study suggests that negative immunostaining of fiberoptic bronchial biopsies for p53 and Ki67
could represent a better prognostic factor for patients with NSCLC.Background
Lung cancer accounts for the most cancer related deaths
in both men and women. Cigarette smoking is by far the
most important risk factor for lung cancer. Risk
increases with quantity and duration of cigarette con-
sumption. The 1-year relative survival for lung cancer
increased up to 40% in the last ten years, largely due to
improvements in surgical techniques and combined
therapies. However, the 5-year survival rate for all stages
combined is only 15%. Despite, the 5-year survival rate
is 50% for cases detected when the disease is still loca-
lized, but only 16% when lung cancers are diagnosed out
of this early stage, screening for early/localized lung can-
cer detection has not yet been proven to reduce
mortality.* Correspondence: ciancio@policlinico.unict.it
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reproduction in any medium, provided the orSome independent prognostic factors have been sug-
gested for predicting survival and helping in the man-
agement of patients with lung cancer. Regarding this
issue, during the last few years there has been a growing
interest in molecular biology of lung cancer. As the mo-
lecular characteristic of cancer have become better
understood, prognostic models have been developed for
lung cancer that incorporate biological markers, immu-
nohistochemical properties and genetic features in
addition to hystologic subtype, age of patients and extent
of disease (TNM-stage). Mutation of the p53 tumor sup-
pressor gene, which is localized on human chromosome
17p13, it has been observed in many human cancers and
is the most common mutation in lung cancers [1]. The
p53 phosphoprotein, a 53-kD nuclear protein produced
by this gene, acts in its wild-type conformation as a
transcription factor and DNA binding protein, and this
activity results on inhibition of cell proliferation by
blocking entry into the S-phase of the cell cycle [2].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proteins with an half-life increased from 20 min to sev-
eral hours, compared with wild-type p53, and conse-
quently accumulate in the nucleus to levels easily
detectable by immunohistochemestry [3]. Since a first
study demonstrated the relevance of p53 immunohisto-
chemical expression in lung cancer [4], several reports
have been carried out on the clinical and prognostic sig-
nificance of p53 alteration in this field, but the results
are not always of univocal interpretation, with a few
meta-analyses inclining towards abnormal p53 status
being associated with poorer prognosis [5,6]. Actually,
there are many publications in which p53 overexpres-
sion, in small biopsies, obtained by bronchoscopy or
transbronchial biopsies, burdens for poor prognosis in
advanced non-small cell lung cancer [7-10].
The antibody Ki67, which recognizes a nuclear antigen
in proliferating cells, has been widely used to estimate
growth fraction in different cancer lesions [11,12]. Des-
pite a large number of studies performed in lung cancer
patients, the prognostic value of Ki-67 for survival
remains controversial and, till now, there are very few
meta-analysis reports on its importance in human lung
cancer [13-19].
Aim of the present study is to determine the correlation
of p53 protein and Ki67 antigen, immunohistochemicallyTable 1 Characteristics of the patients
# Name Sex Age Diagnosis S
1 MS M 68 1
2 SF M 62 1
3 MS M 74 3
4 TP M 74 2
5 SG M 72 1
6 BS M 67 1
7 PG M 57 2
8 GP M 64 2
9 CS M 69 1
10 SS M 83 1
11 PG M 59 1
12 ZF M 66 1
13 RM F 64 2
14 TF F 68 1
15 MS F 59 1
16 CR F 70 2
17 RS M 59 3
18 BA F 64 1
19 BR M 58 1
Age at the time of diagnosis; Smoking more than 10 pack/yrs = +; Diagnosis: 1 = A
diagnosis (months). For p53 and Ki67 + or – see the test.detected in bronchial biopsies, with survival of patients
with non small cell lung cancers.Methods
Patients
We studied samples obtained from 19 consecutive
patients that had been undergone to bronchoscopy, with
diagnostic intent, in our Unit, between January 2008 to
December 2010. We used flexible fiberoptic bronchos-
copy (BF-1 T40; Olympus; Tokyo, Japan) and all samples
were collected by the same operator. Only patients with
positive histological diagnosis entered into the study.
The clinical staging was defined with the usual method
[20]. There were 5 women and 14 men, with ages ran-
ging from 57 to 83 years (mean ± SD, 66.0 ± 6.7). Diag-
nosis of the 19 non-small cell lung cancer (NSCLC)
included: 12 adenocarcinomas, 5 squamous cell carcin-
omas, and 2 in which the hystological pattern was not
clearly identified by the two operators. Thus, in these 2
cases the term of non-small cell lung carcinoma
(NSCLC) not otherwise specified (NOS) was used,
according to the recent revision of NSCLC in small bi-
opsies [21]. The study follow-up lasted to each patient’s
death. Clinicopathological data of all patients are
reported in Table 1.moking Staging p53 Ki67 Survival
+ IIIA + + 2
+ IV + + 4
+ IIB + + 5
+ IIB - - 10
+ IV + + 2
+ IIA + - 14
+ IB + + 4
+ IIIB - - 20
+ IIIB + - 8
+ IIIA - - 17
+ IIA - - 21
- IB - + 6
- IIIB - - 7
+ IIIA + + 5
+ IIB - - 10
- IIA - - 9
+ IIIA + - 5
+ IIIB - + 7
+ IIA - - 15
denocarcinomas, 2 = Squamous Cell, 3 = NSCLC-NOS; Survival: time from the
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Immunohistochemical staining was performed on for-
malin-fixed, paraffin-embedded sections of 5 um with
monoclonal antibodies to the p53 protein (DO-7;
DAKO, Japan) and Ki67 (Ab297M, Biogenex, U.S.A.).
Similar procedures were followed for the usual treat-
ment of deparaffination, with xylene, absolute alcohol
and distilled water. Ki-67 and p53 sections were heated
in a microwave oven 4 times, each of 5 min, in citrate
buffer-solution. The slides, after at least 30 min of air-
drying, were incubated with the primary antibodies
against p53 and Ki67. Dilutions (raging between 1:25
and 1:50) and time of incubation (30 to 60 min) were
depending on the batch of antibody. After washing with
Phosphate Buffered Saline (PBS) secondary antimouse
antibodies were added (biotinylatedantimouseIgG;
Nichirei, Japan) both for Ki-67 or P53. Afterwards the
slides were incubated with streptavidin-peroxidase re-
agent (Nichirei, Japan) and again the time of incubation
was depending by the “data-sheet” of the antibody. After
another PBS wash, the final staining was provided using
a 0,05% solution of diaminobenzidinetetrahydrochloride
in PBS usually for 10 min. Finally, sections were coun-
terstained with Meyer’s haematoxylin. For p53 a tumor
was considered to be immunopositive when the number
of cells with nuclei red-stained exceeded 15% [10], with-
out a semiquantitative classification. Likewise, for Ki67
the “cut-off” point for positivity was considered when
>25% positive cells were observed by counting more
than 1,500 cancer cells randomly selected throughout
each section using a 40x objective [13].Figure 1 Positive immunostaining for p53, adenocarcinoma of the lun
of the lung.Data analysis
The Kaplan-Meier method was used to estimate the
probability of overall survival as a function of time
(starting from the date of diagnostic bronchoscopy to
that of death from cancer), and difference in the survival
of subgroups of patients were compared with Mantel’s
log-rank test. Multivariate analyses were performed
using the Cox regression model to study factors that
independently influenced overall survival. Statistical sig-
nificance was set a P value <0.005 and all test were two-
tailed as were the reported P values.
Results
We found p53 reactivity in 9 of the patients (47.37%).
The antibody used in this study reacts with wild type
and mutant type of the p53 protein and the nuclear re-
activity, as expressed before in “Methods” section, was
designed to be “positive” (+ve). For Ki67 immunostain-
ing, reactivity between antibody and antigen localised in
nuclei of proliferating cells, designed + ve as above indi-
cated, was found in 8 of the patients (42.10%). By con-
trast we designed as “negative” (−ve) reactivity against
p53 antibodies or Ki67 under the “cut-off” points of 15%
for p53 and 25% for Ki67. Only tumoral section showed
immunoreactivity both for p53 or Ki67, indicating that
our immunostaining procedures do not generate false
positives. In Figures 1a and 1b we shown photomicro-
graphs of p53 + ve and Ki67 + ve sections of different
histotypes are shown.
We compared Kaplan-Meier survival curves for the
p53 and Ki67 + ve groups and p53 and Ki67 –ve groupsg. b: Positive immunostaining for Ki67, squamous cell carcinoma
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found that both p53 –ve (median survival: 10 months)
and Ki67 –ve (median survival: 10 months) patients had
a significantly higher survival rates than p53 + ve (log
rank test, p < 0.005, median survival 5 months) and
Ki67 + ve (log rank test, p < 0,0001, median survival 4.5
months). Multivariate analysis (Cox proportional hazard
model) for age, sex, smoking history, TNM stage, and
overexpression of p53 and ki67 was performed to exam-
ine the interrelationship of possible prognostic factors
and survival (Table 2). In all cases, p53 and ki67 overe-
pression were statistically identified as independent
prognostic factors predicting poor survival with aFigure 2 a: Overall-survival of all patients included in the study,
with p53 immunohistochemicalresults. b: Overall-survival of all
patients included in the study, with Ki67 immunohistochemical
results.relative risk of 15.31 (p < 0.005) and 19.09 (p < 0.005),
respectively. The other studied variables did not show a
statistical correlation as independent prognostic factor
with survival.Discussion
First histological diagnosis of lung cancer is often
obtained by fiberoptic bronchial biopsies. However the
utility of extend histological studies with immunohisto-
chemical methods in lung cancer is still debated. We
have shown the feasibility of immunohistochemical de-
tection of p53 and Ki67 in bronchial biopsies, performed
with diagnostic intent, in patients with histological diag-
nosis of NSCLC. In our study, the incidence of p53 posi-
tivity in NSCLC was 47.34%, and it was 42.1% for Ki67
positivity. Furthermore, utilizing these small biopsy lung
specimens we compared p53 and Ki67 positivity with
survival rate. There are few studies describing p53 over-
expression in samples obtained in a non surgical setting
and it relationship to survival rate [7-10,22-24].
Murakami and coll. [23] examined 25 specimens, from
bronchial biopsies, of 23 patients, and they were able to
detect p53 gene mutations in 10 of 25 (40%) of broncho-
scopic biopsy specimens. These authors, who studied
altogether 206 specimens from 66 patients obtained with
different sampling methods, such as bronchial biopsy,
brushing, washing, thoracentesis and percutaneous nee-
dle aspiration, concluded that p53 mutation is associated
with a poor prognosis in patients with advanced NSCLC.
A larger sample of patients was studied by Kawasaki and
coll. [9] with transbronchial biopsies. They found 98
p53-positive immunostaining patients from a total of
175 (56%), and regarding NSCLC 61 p53-positive from a
total of 111 patients (55%). Also in this study, a significa-
tive poor prognosis was found only in patients with
stages III/IV and p53 positive immunostaining. Never-
theless, the first study in which p53 positivity was related
to poor prognosis was that of Quinland and coll. [25].
They studied 49 NSCLC cases of stage I or II patients
surgically-treated, and they found a significative relation-
ship between p53 accumulation and poor prognosis.
Their immunohistochemistry method is similar to our,
with a monoclonal antibody that recognizes both mutant
and wild-type forms of p53 protein. By contrast, subse-
quent studies not always confirmed results of Quinland
and coll. of the relevance of p53 immunostaining in
the early stages as a prognostic factor of lung cancer
[26-31]. In our study, most patients received only pallia-
tive care, or did not complete the chemotherapy (kt)
treatment, and only 6 patients were surgically treated.
This could be a confusing factor of our statistical ana-
lysis. In fact, positive p53 staining seems to be correlated
with unresponsiveness to kt in NSCLC [10] and p53
Table 2 Cox proportional hazard model analysis of survival time
Covariate Coefficient b SEM P Exp (b) 95% CI of Exp(b)
Age (<65 vs. >65 yrs) −0,5287 0,7819 0,4989 0,5894 0,1283 to 2,7076
Ki67 (+ve vs. –ve) 2,9491 0,9966 0,003085 19,0890 2,7339 to 133,2877
p53 (+ve vs. –ve) 2,7283 0,9849 0,004904 15,3068 2,2428 to 104,4664
Sex (M vs. F) −0,3679 0,6455 0,5688 0,6922 0,1966 to 2,4374
Smoking History −2,3558 1,0740 0,02827 0,0948 0,0117 to 0,7699
(Smoker vs. Not-smokers)
TNM Stage (I-IIIA vs. IIIB-IV) 0,3726 0,6508 0,5670 1,4515 0,4080 to 5,1642
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cells to anticancer agents [32].
The use of Ki67 immunostainining in lung cancer is
not easy to apply and the feasibility of Ki67 in specimens
of small size like the bronchial biopsies is still controver-
sial.Scagliottiet all. [14] firstly indicated that patients
with a higher Ki67 score (>25% positive cells) at diagno-
sis had a significantly lower disease-free survival. In the
present study, we have chosen a similar “cut-off point”: a
percentage of stained tumour cell greater than 25%, and
the results were in accordance with other ones regarding
feasibility in small size specimens [33]. Afterwards, other
studies investigated the role of Ki67 overexpression in
NSCLC [15,34] demonstrating that it was associated
with unfavourable clinical outcome.
Simultaneous expression of p53 and Ki67 was studied
as a prognostic factor in resected lung cancer [16]. Sur-
prisingly, these authors found that combination p53
positivity and low Ki67 expression may represent a
favourable prognostic factor. Few years ago, prognostic
significance of p53 and Ki67 immunocytochemical ex-
pression was studied in surgically treated NSCLC [17].
These authors found a significative statistical correlation
only in p53-positive smears in patients of stage 1 and
particularly in patients with adenocarcinoma subtype.Conclusion
We have shown the utility of p53 and Ki67 immunos-
taining of bronchial biopsies in NSCLC. Our data indi-
cate that p53 and Ki67 immunostaining of small size
specimens obtained during diagnostic procedures with
fiberoptic bronchoscopy may be useful in predicting
prognosis in patients with NSCLC. The incidence of
immunohistochemical positivity in NSCLC was approxi-
mately the same as reported in other studies, and, fur-
thermore, no histologically negative samples was stained,
thus indicating the validity of our method. However,
these results were obtained in a relatively small number
of patients, such as we were not able to predict a rela-
tionship between positive immunostaining and resist-
ance to chemotherapy.We believe that a simple, inexpensive method, as that
reported in the present study should be useful in pre-
dicting prognosis of patients with NSCLC. More studies
are needed to understand the possible relationship of
positive stain for p53 and Ki67 with the resistance to
chemotherapy.
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